Related Experiment Video
Updated: Jun 11, 2026
11:57
Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Yeast as a model for studying Alzheimer's disease
Prashant Bharadwaj1, Ralph Martins, Ian Macreadie
1Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise, Biomedical & Health Sciences, Edith Cowan University, Perth, WA, Australia.
FEMS Yeast Research
|July 13, 2010
Summary
Alzheimer's disease (AD) research utilizes yeast models to understand pathological protein misfolding. This summary explores how yeast helps decipher molecular mechanisms underlying AD pathogenesis and neuronal cell loss.
Area of Science:
- Neurodegenerative diseases
- Molecular biology
- Yeast genetics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing cognitive decline.
- AD pathology includes amyloid plaques, neurofibrillary tangles, and neuronal loss.
- Mechanisms of neuronal dysfunction in AD are not fully understood.
Purpose of the Study:
- To summarize knowledge from studies using yeast models to investigate Alzheimer's disease pathogenesis.
- To explore the utility of yeast as a model for neurodegenerative disorders.
Main Methods:
- Review of existing literature on yeast models in Alzheimer's disease research.
- Analysis of studies focusing on protein misfolding and deposition pathways in yeast.
- Integration of findings related to molecular mechanisms of AD.
Main Results:
- Yeast serves as a valuable model for studying molecular pathways in neurodegenerative conditions.
- Yeast models facilitate the investigation of pathological protein aggregation relevant to AD.
- Studies in yeast have provided insights into cellular dysfunction in AD.
Conclusions:
- Yeast is a powerful tool for dissecting the molecular underpinnings of Alzheimer's disease.
- Further research using yeast models can elucidate mechanisms of neuronal cell loss in AD.
- Understanding these mechanisms in yeast can contribute to developing therapeutic strategies for AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:28Yeast Signaling
Yeasts are single-celled organisms, but unlike bacteria, they are eukaryotes (cells with a nucleus). Cell signaling in yeast is similar to signaling in other eukaryotic cells. A ligand, such as a protein or a small molecule released from a yeast cell, attaches to a receptor on the cell surface. The binding stimulates second-messenger kinases to activate or inactivate transcription factors that further regulate gene expression. Many of the yeast intracellular signaling cascades have similar...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...